Safety Study of iCo-007 Intravitreal Injection to Treat Diabetic Macular Edema

Summary

The goal of the study is to evaluate the safety and tolerability of 4 different doses of iCo-007 Intravitreal Injection in patients with diffuse diabetic macular edema.

Timeline

Start

2008-02

Primary completion

2010-05

Completion

2010-06

Outcome

Met primary endpoint

release “its Phase I clinical trial for iCo-007 in patients with diffuse diabetic macular edema has met its primary end point.” icotherapeutics.com ↗

release “On May 17, 2010, the Company announced the results from the Phase I trial for iCo-007 with the trial meeting its primary endpoint.” icotherapeutics.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	iCo-007	Unknown	110 ug	Intravitreal
Subject	iCo-007	Unknown	350 ug	Intravitreal
Subject	iCo-007	Unknown	700 ug	Intravitreal
Subject	iCo-007	Unknown	1000 ug	Intravitreal

Indications